Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CANOPY-N: Neoadjuvant Canakinumab and Pembrolizumab in NSCLC
NCT03968419Phase 2Terminated
- Sponsor
- Novartis
- Start
- Nov 2019
- Primary completion
- Apr 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 12
01
Overview
Phase 2, randomised, open-label trial of canakinumab in non-small cell lung cancer (NSCLC), sponsored by Novartis. Primary endpoint: Major Pathological Response Rate at 6 weeks. Started Nov 2019; status: terminated.
02
Drugs
canakinumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03968419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03968419.